|
One Step Dementia Risk Test Kit
The kit uses colloidal gold lateral immunochromatography to detect Aβ in urine, delivering a risk alert in 10 minutes. It targets the operational gap between expensive imaging and routine primary care.
Dementia diagnosis has long relied on CSF analysis or PET imaging — both costly and inaccessible outside specialised neurology centres. The One Step Dementia Risk Test Kit collapses this workflow into a single lateral flow strip, using a midstream urine sample and a detection time of ten minutes.
The biomarker is urinary Aβ concentration, measured via an antibody-polymer sandwich method with an in-house developed monoclonal antibody. Sensitivity sits at 79.14% and specificity at 91.03%, with a kappa value of 0.704. These figures place it as an auxiliary screening device — a triage tool, not a confirmatory diagnostic.
It holds CE and NMPA certification and is marketed as the first global product in its category. That regulatory pathway is itself revealing: China’s IVD industry has moved from reagent assembly to owning the core antibody IP and the kit-level design.
The intended user is not a neurologist but a general practitioner or health screening centre processing patients aged 45 and above. The kit removes the need for venipuncture, cold chain logistics for samples, and laboratory infrastructure. That makes it deployable in community hospitals, corporate wellness programmes, and rural screening campaigns.
The product also reveals a procurement logic shift. Bulk buyers — municipal health bureaus, insurance schemes, large clinical chains — now have a cost-effective, standardisable unit that fits into existing physical exam batteries. The per-test economics favour scale over margin.
What looks like a simple test strip is actually a supply-chain intervention: turning dementia risk assessment into a consumable that can be ordered, stocked, and administered like a pregnancy test.
Why it matters:
For procurement teams and health system operators, this kit represents a bridge between early detection and primary care logistics. It reduces the cost and complexity of large-scale cognitive screening, especially in settings without immediate access to neurology specialists or advanced imaging.
View Product →
|
ScientificChina — tracking China’s science, technology, and industrial systems through the lens of real-world products.
Follow ScientificChina for deeper insight into the infrastructure behind global innovation.
Visit ScientificChina.
|
|
No products in the cart.